TAC to the future. Plus: GSK’s Rapt deal, codifying MFN — a BioCentury podcast

How next-generation targeting chimeras are gaining traction. Plus: GSK’s $2.2B takeout, Washington policy update and JPM takeaways

Next-generation induced proximity technologies are coming of age after a decade of industry focus on PROTACs. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss Senior Biopharma Analyst Danielle Golovin’s four-part analysis of how next-generation targeting chimeras (TACs) are evolving.

The analysts assess the $2.2 billion takeout of  Rapt Therapeutics Inc. (NASDAQ:RAPT) by GSK plc (LSE:GSK; NYSE:GSK), which gave the pharma an allergy asset that the biotech sourced in China in 2024, and movement in Washington on priority review vouchers, NIH’s budget and the White House’s “most favored nation” drug pricing policy. The analysts also discuss takeaways from their meetings on the sidelines of the J.P. Morgan Healthcare Conference.